These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 27079211)

  • 1. Significance of survivin as a prognostic factor and a therapeutic target in endometrial cancer.
    Chuwa AH; Sone K; Oda K; Ikeda Y; Fukuda T; Wada-Hiraike O; Inaba K; Makii C; Takeuchi M; Oki S; Miyasaka A; Kashiyama T; Arimoto T; Kuramoto H; Kawana K; Yano T; Osuga Y; Fujii T
    Gynecol Oncol; 2016 Jun; 141(3):564-569. PubMed ID: 27079211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted BIRC5 silencing using YM155 causes cell death in neuroblastoma cells with low ABCB1 expression.
    Lamers F; Schild L; Koster J; Versteeg R; Caron HN; Molenaar JJ
    Eur J Cancer; 2012 Mar; 48(5):763-71. PubMed ID: 22088485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survivin selective inhibitor YM155 induce apoptosis in SK-NEP-1 Wilms tumor cells.
    Tao YF; Lu J; Du XJ; Sun LC; Zhao X; Peng L; Cao L; Xiao PF; Pang L; Wu D; Wang N; Feng X; Li YH; Ni J; Wang J; Pan J
    BMC Cancer; 2012 Dec; 12():619. PubMed ID: 23267699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug screening and grouping by sensitivity with a panel of primary cultured cancer spheroids derived from endometrial cancer.
    Kiyohara Y; Yoshino K; Kubota S; Okuyama H; Endo H; Ueda Y; Kimura T; Kimura T; Kamiura S; Inoue M
    Cancer Sci; 2016 Apr; 107(4):452-60. PubMed ID: 26825848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Putative tumor suppression function of SIRT6 in endometrial cancer.
    Fukuda T; Wada-Hiraike O; Oda K; Tanikawa M; Makii C; Inaba K; Miyasaka A; Miyamoto Y; Yano T; Maeda D; Sasaki T; Kawana K; Fukayama M; Osuga Y; Fujii T
    FEBS Lett; 2015 Aug; 589(17):2274-81. PubMed ID: 26183563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. YM155 induces apoptosis through downregulation of specificity protein 1 and myeloid cell leukemia-1 in human oral cancer cell lines.
    Sachita K; Yu HJ; Yun JW; Lee JS; Cho SD
    J Oral Pathol Med; 2015 Nov; 44(10):785-91. PubMed ID: 25475012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting survivin with YM155 (Sepantronium Bromide): a novel therapeutic strategy for paediatric acute myeloid leukaemia.
    Smith AM; Little EB; Zivanovic A; Hong P; Liu AK; Burow R; Stinson C; Hallahan AR; Moore AS
    Leuk Res; 2015 Apr; 39(4):435-44. PubMed ID: 25659731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small Molecule Survivin Inhibitor YM155 Displays Potent Activity Against Human Osteosarcoma Cells.
    Zhang S; Wang X; Gu Z; Wang L
    Cancer Invest; 2016 Sep; 34(8):401-7. PubMed ID: 27559851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. YM155 Down-Regulates Survivin and Induces P53 Up-Regulated Modulator of Apoptosis (PUMA)-Dependent in Oral Squamous Cell Carcinoma Cells.
    Yan X; Su H
    Med Sci Monit; 2017 Apr; 23():1963-1972. PubMed ID: 28435150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor effect of YM155, a novel small-molecule survivin suppressant, via mitochondrial apoptosis in human MFH/UPS.
    Minoda M; Kawamoto T; Ueha T; Kamata E; Morishita M; Harada R; Toda M; Onishi Y; Hara H; Kurosaka M; Akisue T
    Int J Oncol; 2015 Sep; 47(3):891-9. PubMed ID: 26166250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. YM155 sensitizes ovarian cancer cells to cisplatin inducing apoptosis and tumor regression.
    Mir R; Stanzani E; Martinez-Soler F; Villanueva A; Vidal A; Condom E; Ponce J; Gil J; Tortosa A; Giménez-Bonafé P
    Gynecol Oncol; 2014 Jan; 132(1):211-20. PubMed ID: 24262875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survivin inhibitor YM155 suppresses gastric cancer xenograft growth in mice without affecting normal tissues.
    Cheng XJ; Lin JC; Ding YF; Zhu L; Ye J; Tu SP
    Oncotarget; 2016 Feb; 7(6):7096-109. PubMed ID: 26771139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BIRC5 expression is a poor prognostic marker in Ewing sarcoma.
    Hingorani P; Dickman P; Garcia-Filion P; White-Collins A; Kolb EA; Azorsa DO
    Pediatr Blood Cancer; 2013 Jan; 60(1):35-40. PubMed ID: 22961763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical efficacy of sepantronium bromide (YM155) in multiple myeloma is conferred by down regulation of Mcl-1.
    Wagner V; Hose D; Seckinger A; Weiz L; Meißner T; Rème T; Breitkreutz I; Podar K; Ho AD; Goldschmidt H; Krämer A; Klein B; Raab MS
    Oncotarget; 2014 Nov; 5(21):10237-50. PubMed ID: 25296978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Action of YM155 on clear cell renal cell carcinoma does not depend on survivin expression levels.
    Sim MY; Huynh H; Go ML; Yuen JSP
    PLoS One; 2017; 12(6):e0178168. PubMed ID: 28582447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor activity of YM155, a selective small-molecule survivin suppressant, alone and in combination with docetaxel in human malignant melanoma models.
    Yamanaka K; Nakahara T; Yamauchi T; Kita A; Takeuchi M; Kiyonaga F; Kaneko N; Sasamata M
    Clin Cancer Res; 2011 Aug; 17(16):5423-31. PubMed ID: 21737502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. YM155, a novel survivin suppressant, enhances taxane-induced apoptosis and tumor regression in a human Calu 6 lung cancer xenograft model.
    Nakahara T; Yamanaka K; Hatakeyama S; Kita A; Takeuchi M; Kinoyama I; Matsuhisa A; Nakano K; Shishido T; Koutoku H; Sasamata M
    Anticancer Drugs; 2011 Jun; 22(5):454-62. PubMed ID: 21389848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. YM155 Reverses Statin Resistance in Renal Cancer by Reducing Expression of Survivin.
    Nitta T; Koike H; Miyao T; Miyazawa Y; Kato H; Furuya Y; Sekine Y; Suzuki K
    Anticancer Res; 2017 Jan; 37(1):75-80. PubMed ID: 28011476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic potential of sepantronium bromide YM155 in gemcitabine-resistant human urothelial carcinoma cells.
    Huang YT; Cheng CC; Lin TC; Chiu TH; Lai PC
    Oncol Rep; 2014 Feb; 31(2):771-80. PubMed ID: 24297644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The over-expression of survivin enhances the chemotherapeutic efficacy of YM155 in human hepatocellular carcinoma.
    Xia H; Chen J; Shi M; Deivasigamani A; Ooi LL; Hui KM
    Oncotarget; 2015 Mar; 6(8):5990-6000. PubMed ID: 25714025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.